In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products
In this study, we first predicted the degradation pathways and impurities of model pharmaceuticals, namely gliclazide and indapamide, in silico using an expert-knowledge software. Second, we verified the prediction results with a demonstration test, which confirmed that N-nitrosamines formed from the degradation of gliclazide and indapamide in the presence of hydrogen peroxide, especially under alkaline conditions. Furthermore, the pathways by which degradation products formed were determined using ranitidine, a compound previously demonstrated to generate NDMA. The prediction indicated that a ranitidine-related compound s...
Source: Chemical and Pharmaceutical Bulletin - January 31, 2024 Category: Drugs & Pharmacology Authors: Genichiro Tsuji Takashi Kurohara Takuji Shoda Hidetomo Yokoo Takahito Ito Sayaka Masada Nahoko Uchiyama Eiichi Yamamoto Yosuke Demizu Source Type: research
Cost-effectiveness of ultra-low-dose quadruple combination therapy for high blood pressure
Conclusion(s)
Quadpill in comparison with monotherapy is comparably cost-effective for short-term BP lowering. In the long-term, quadpill therapy is likely to be cost-effective.
Trial registration number
ANZCTRN12616001144404. (Source: Heart)
Source: Heart - October 26, 2023 Category: Cardiology Authors: Atkins, E. R., Chye, A., Lung, T., Nolde, J. M., Billot, L., Burke, M., Chalmers, J., Figtree, G. A., Hay, P., Hillis, G. S., Jansen, S., Marschner, S., Neal, B., Nelson, M. R., Reid, C. M., Usherwood, T., Schlaich, M., Chow, C. K., Rodgers, A. Tags: Healthcare delivery, economics and global health Source Type: research
Pharmacokinetics and Drug –Drug Interaction of Allisartan Isoproxil and Indapamide Sustained‐Release Formulation
AbstractAllisartan isoproxil (AI) is an angiotensin II type 1 receptor blocker and be converted into the active substance EXP3174 in vivo. We evaluated the drug –drug interactions of AI and an indapamide sustained-release (Ind SR) preparation, as well as the pharmacokinetic characteristics and safety of AI and Ind SR in healthy subjects. The trial was set up in 6 sequences and 3 cycles, and each cycle contained a 7-day washout period. Subjects received 3 different trial drugs (A, AI; B, Ind SR; C, AI + Ind SR) during 3 different cycles. Twenty-four subjects were enrolled in the clinical trial. Of these, 22 completed th...
Source: Clinical Pharmacology in Drug Development - October 18, 2023 Category: Drugs & Pharmacology Authors: Wu Yi,
Sisi Lin,
Rui Hao,
Yiming Shao,
Yannan Wang,
Jin Yu,
Lu Fang,
Jingjing Zhu,
Aiwei Wang,
Yanfang Wu,
Hua Huang,
Chongyang Deng,
Jingchao Sun,
Hongcan Zhao,
Ying Wang,
Xiangming Tong Tags: Original Article Source Type: research
Genes, Vol. 14, Pages 1878: A Spanish Family with Gordon Syndrome Due to a Variant in the Acidic Motif of WNK1
Conclusions: This is the first Spanish family with GS with a novel heterozygous missense variant in WNK1 (p.Glu630Gly) in the region containing the highly conserved acidic motif, which is showing a relatively mild phenotype, and adults diagnosed in mild adulthood. These data support the importance of missense variants in the WNK1 acidic domain in electrolyte balance/metabolism. In addition, findings in this family also suggest that indapamide retard or thiazide may be an adequate long-standing treatment for GS. (Source: Genes)
Source: Genes - September 27, 2023 Category: Genetics & Stem Cells Authors: Ram ón Peces Carlos Peces Laura Espinosa Roc ío Mena Carolina Blanco Jair Tenorio-Casta ño Pablo Lapunzina Juli án Nevado Tags: Article Source Type: research
Comparison of Pharmacokinetics and Bioavailability of Fixed ‐Dose Combination Tablet and Monotherapy Combination of Allisartan Isoproxil and Indapamide Sustained‐Release in Healthy Chinese Volunteers
This study aimed to compare the pharmacokinetics and bioavailability of 2 formulations: a fixed-dose combination tablet containing allisartan isoproxil (AI) and indapamide sustained-release (SR), and a monotherapy combination of AI and indapamide SR, in healthy Chinese subjects. A monocentric, open-label, single-dose, randomized, 2-way crossover study design was implemented. A total of 38 healthy male and female volunteers were equally divided into 2 treatment sequences. The analysis of plasma concentrations was conducted using a nonstereospecific liquid chromatography/tandem mass spectrometric method. The primary pharmaco...
Source: Clinical Pharmacology in Drug Development - September 11, 2023 Category: Drugs & Pharmacology Authors: Ni Fan,
Zhou Gongmin,
Cheng Wenming,
Yang Jiao,
Zhang Ruijie,
Chen Yan,
Tong Xiangming,
Wu Yi Tags: Original Article Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients
CONCLUSIONS: The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.PMID:37634155 | DOI:10.1556/650.2023.32840 (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - August 27, 2023 Category: General Medicine Authors: G ábor Simonyi Tam ás Ferenci Ervin Finta Mih ály Medvegy Istv án Wittmann Source Type: research
Every second counts: giant ECG abnormality after every second beat
Clinical introduction The patient had recently been diagnosed with heart failure and dilated cardiomyopathy (left ventricular ejection fraction: 20%). Medication included furosemide, spironolactone, bisoprolol, perindopril, indapamide. The patient was found with a cardiac arrest. After successful basic life support and stabilized circulation, the following ECG was recorded (see figure 1). Question What is the possible explanation for these ECG features? Giant TU waves due to proarrhythmic effect of propafenone (Class 1/c antiarrhythmic drug) the patient was given as paroxysmal atrial fibrillation rhythm control. Hypokalaem...
Source: Emergency Medicine Journal - July 24, 2023 Category: Emergency Medicine Authors: Tomcsanyi, J., Aranyi, P. Tags: EMJ Image Challenge Source Type: research
Change in Echocardiographic Parameters in Patients Receiving a Quadruple Ultra-Low-Dose Anti-Hypertensive Combination for Treatment of Hypertension
This group has previously demonstrated greater blood pressure (BP)-lowering effects using a quadruple ultra-low-dose combination of anti-hypertensives (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg) ( “quadpill”) compared with standard monotherapy (irbesartan 150 mg). It sought to compare changes in echocardiographic parameters between the two groups after 12 months of treatment. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: P. Emerson, M. Schlaich, A. Rajwani, C. Chow, G. Hillis, L. Thomas Source Type: research
